Exact Sciences Reports Positive Developments, But Remains Unprofitable and Mediocre Guidance for 2023.

Trending News ☀️

Overall, Exact Sciences ($NASDAQ:EXAS) reported some positive developments in their Q4 results, but the company is still unprofitable and their outlook for 2023 is merely mediocre. They also reported an expansion in their total addressable market, with their test volume and average revenue per patient increasing.

However, while they are seeing some developments in their business, they are still far from being profitable. Furthermore, the company provided guidance for 2023 that was not overly optimistic. They expect their operating expenses to stay relatively flat and their operating margin to remain below 1%. This is clearly not very encouraging news for investors. In conclusion, Exact Sciences is seeing some positive developments in their business, but still remain far from profitability. Moreover, their 2023 guidance is merely average at best.

Share Price

Exact Sciences reported positive developments on Wednesday, which caused their stock to open at $62.0 before eventually closing at $62.4, representing a 0.2% increase from their prior closing price of $62.3. Despite these positive developments, the company remains unprofitable and has delivered mediocre guidance for 2023. Currently, Exact Sciences remains behind its peers in terms of profitability and performance, though their recent developments suggest that the company is taking steps towards improving their financial situation. It will be interesting to monitor Exact Sciences’ progress in the coming year as they attempt to reach their goals. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Analysis

At GoodWhale, we have conducted an analysis on EXACT SCIENCES‘ fundamentals and are providing our findings below. After examining their financial performance, our star chart gave it a dismal health score of 2/10, indicating that the company is not likely to sustain operations in times of crisis. EXACT SCIENCES has been classified as a ‘cheetah’ type of company, which means it has achieved high revenue or earnings growth, but is considered less stable due to its lower profitability. Given EXACT SCIENCES’ strengths in growth and weakness in asset, dividend, and profitability, our findings suggest that more aggressive investors may be interested in this company. For those looking for a more conservative approach, it is important to understand the risks associated with an investment in EXACT SCIENCES. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Exact Sciences Corporation is an oncology diagnostics company that has recently released financial results and outlooks. Despite the positive developments, the company has remained unprofitable. Investor sentiment may be mixed on these results as the company seems to focus more on growth and market penetration than true profitability.